919 related articles for article (PubMed ID: 19751997)
1. [Cancer genetics: estimation of the needs of the population in France for the next ten years].
Bonaïti-Pellié C; Andrieu N; Arveux P; Bonadona V; Buecher B; Delpech M; Jolly D; Julian-Reynier C; Luporsi E; Noguès C; Nowak F; Olschwang S; Orsi F; Pujol P; Saurin JC; Sinilnikova O; Stoppa-Lyonnet D; Thépot F
Bull Cancer; 2009 Sep; 96(9):875-900. PubMed ID: 19751997
[TBL] [Abstract][Full Text] [Related]
2. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions.
Lancaster JM; Powell CB; Kauff ND; Cass I; Chen LM; Lu KH; Mutch DG; Berchuck A; Karlan BY; Herzog TJ;
Gynecol Oncol; 2007 Nov; 107(2):159-62. PubMed ID: 17950381
[TBL] [Abstract][Full Text] [Related]
3. Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome.
Shulman LP
Obstet Gynecol Clin North Am; 2010 Mar; 37(1):109-33, Table of Contents. PubMed ID: 20494261
[TBL] [Abstract][Full Text] [Related]
4. Genetic testing for familial cancer. The French National Report (year 2003).
Eisinger F
Community Genet; 2008; 11(1):63-7. PubMed ID: 18196919
[TBL] [Abstract][Full Text] [Related]
5. [Recommendations for the management of women with an increased genetic risk of gynaecological cancer].
Verheijen RH; Boonstra H; Menko FH; de Graaff J; Vasen HF; Kenter GG
Ned Tijdschr Geneeskd; 2002 Dec; 146(50):2414-8. PubMed ID: 12518519
[TBL] [Abstract][Full Text] [Related]
6. Screening and prevention of hereditary gynecologic cancers.
Kehoe SM; Kauff ND
Semin Oncol; 2007 Oct; 34(5):406-10. PubMed ID: 17920895
[TBL] [Abstract][Full Text] [Related]
7. Lack of referral for genetic counseling and testing in BRCA1/2 and Lynch syndromes: a nationwide study based on 240,134 consultations and 134,652 genetic tests.
Pujol P; Lyonnet DS; Frebourg T; Blin J; Picot MC; Lasset C; Dugast C; Berthet P; de Paillerets BB; Sobol H; Grandjouan S; Soubrier F; Buecher B; Guimbaud R; Lidereau R; Jonveaux P; Houdayer C; Giraud S; Olschwang S; Nogue E; Galibert V; Bara C; Nowak F; Khayat D; Nogues C
Breast Cancer Res Treat; 2013 Aug; 141(1):135-44. PubMed ID: 23974829
[TBL] [Abstract][Full Text] [Related]
8. Review article: Detection and management of hereditary non-polyposis colorectal cancer (Lynch syndrome).
Ramsoekh D; Van Leerdam ME; Wagner A; Kuipers EJ
Aliment Pharmacol Ther; 2007 Dec; 26 Suppl 2():101-11. PubMed ID: 18081654
[TBL] [Abstract][Full Text] [Related]
9. Cancer patients who experienced diagnostic genetic testing for cancer susceptibility: reactions and behavior after the disclosure of a positive test result.
Bonadona V; Saltel P; Desseigne F; Mignotte H; Saurin JC; Wang Q; Sinilnikova O; Giraud S; Freyer G; Plauchu H; Puisieux A; Lasset C
Cancer Epidemiol Biomarkers Prev; 2002 Jan; 11(1):97-104. PubMed ID: 11815406
[TBL] [Abstract][Full Text] [Related]
10. Hereditary breast and ovarian cancer: epidemiology, genetics, screening and predictive testing.
Foulkes WD; Narod SA
Clin Invest Med; 1995 Dec; 18(6):473-83. PubMed ID: 8714791
[TBL] [Abstract][Full Text] [Related]
11. Genetic testing in gastroenterology: Lynch syndrome.
Grover S; Syngal S
Best Pract Res Clin Gastroenterol; 2009; 23(2):185-96. PubMed ID: 19414145
[TBL] [Abstract][Full Text] [Related]
12. Comparison of individuals opting for BRCA1/2 or HNPCC genetic susceptibility testing with regard to coping, illness perceptions, illness experiences, family system characteristics and hereditary cancer distress.
van Oostrom I; Meijers-Heijboer H; Duivenvoorden HJ; Bröcker-Vriends AH; van Asperen CJ; Sijmons RH; Seynaeve C; Van Gool AR; Klijn JG; Tibben A
Patient Educ Couns; 2007 Jan; 65(1):58-68. PubMed ID: 16872788
[TBL] [Abstract][Full Text] [Related]
13. [Genetic predisposition and ovarian cancer].
Coupier I; Gauthier-Villars M; This P; Stoppa-Lyonnet D
Rev Prat; 2004 Oct; 54(16):1757-62. PubMed ID: 15630879
[TBL] [Abstract][Full Text] [Related]
14. Issues in the genetic assessment of predispositions for familial breast and ovarian cancer.
Mark HF; McGowan KD
Cytobios; 1996; 87(351):229-35. PubMed ID: 9214724
[TBL] [Abstract][Full Text] [Related]
15. Hereditary breast-ovarian cancer: clinical findings and medical management.
Marshall M; Solomon S
Plast Surg Nurs; 2007; 27(3):124-7. PubMed ID: 17901820
[TBL] [Abstract][Full Text] [Related]
16. Psychological impact of genetic testing for cancer susceptibility: an update of the literature.
Meiser B
Psychooncology; 2005 Dec; 14(12):1060-74. PubMed ID: 15937976
[TBL] [Abstract][Full Text] [Related]
17. BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark.
Soegaard M; Kjaer SK; Cox M; Wozniak E; Høgdall E; Høgdall C; Blaakaer J; Jacobs IJ; Gayther SA; Ramus SJ
Clin Cancer Res; 2008 Jun; 14(12):3761-7. PubMed ID: 18559594
[TBL] [Abstract][Full Text] [Related]
18. Influence of race/ethnicity on genetic counseling and testing for hereditary breast and ovarian cancer.
Forman AD; Hall MJ
Breast J; 2009; 15 Suppl 1():S56-62. PubMed ID: 19775331
[TBL] [Abstract][Full Text] [Related]
19. Can we identify the high-risk patients to be screened? A genetic approach.
Gammon A; Kohlmann W; Burt R
Digestion; 2007; 76(1):7-19. PubMed ID: 17947814
[TBL] [Abstract][Full Text] [Related]
20. Hereditary breast cancer: from bench to bedside.
De Grève J; Sermijn E; De Brakeleer S; Ren Z; Teugels E
Curr Opin Oncol; 2008 Nov; 20(6):605-13. PubMed ID: 18841041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
